Poly-ε-caprolactone microspheres containing interferon alpha as alternative formulations for the treatment of chronic hepatitis C

Brazilian Journal of Pharmaceutical Sciences

Volumn 48, Issue 1, 2012, Pages 51-59

  Melo, Cristiane da Silva ^a   Pereira, Bruno Gonçalves ^b   Silva Cunha, Armando ^a   Fialho, Sílvia Ligório ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

Author keywords

Hepatitis C treatment; Interferon alfa; Poly e caprolactone microspheres development

Indexed keywords

ALPHA INTERFERON; DICHLOROMETHANE; HUMAN SERUM ALBUMIN; MICROSPHERE; PHOSPHATE BUFFERED SALINE; POLOXAMER; POLYCAPROLACTONE; SOLVENT;

ARTICLE; CHEMICAL COMPOSITION; CHRONIC HEPATITIS; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; EVAPORATION; FREEZE DRYING; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CULTURE; PARTICLE SIZE; SURFACE PROPERTY; THERMOSTABILITY; ZETA POTENTIAL;

EID: 84861470249     PISSN: 19848250     EISSN: 21759790     Source Type: Journal    
DOI: 10.1590/s1984-82502012000100006     Document Type: Article

References (27)

1. ALMEIDA, A.J.; SOUTO, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev., v.59, p.478-490, 2007.
2. BARBAULT-FOUCHER, S.; GREF, R.; RUSSO, P.; GUECHOT, J.; BOCHOT, A. Design of poly-e-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. J. Control. Release, v.83, p.365-375, 2002.
3. BEILHARZ, M.W. Therapeutic potential for orally administered type 1 interferons. PSTT, v.3, 193-197, 2000.
4. BLANCO, M.D.; BERNARDO, M.V.; SASTRE, R.L.; OLMO, R.; MUNIZ, E.; TEIJO, J.M. Preparation of bupivacaine-loaded poly(e-caprolactone) microspheres by spray drying: drug release studies and biocompatibility. Eur. J. Pharm. Biopharm., v.55, p.229-236, 2003.
5. CHAWLA, J.S.; AMIJI, M.M. Biodegradable poly(e-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int. J. Pharm., v.249, p.127-138, 2002.
6. DASH, A.K.; CUDWORTH II, G.C. Therapeutic applications of implantable drug delivery systems. J. Pharmacol. Toxicol. Methods, v.40, p.1-12, 1998.
7. FERREIRA, M.S.; CARVALHO, A.M. Hepatites. In: ROCHA, M.O.C.; PEDROSO, E.R.P.; FONSECA, J.G.M.; SILVA, A.O. (Eds). Terapêutica clínica. Rio de Janeiro: Guanabara Koogan, 1998. p.1043-1051.
8. HUA, H.; JO, R.J.; YEON, J.H.; HONG, J.T.; JUNG, K.H.; YOO, S.K.; JANG, B.C. Preparation of branched dextran microspheres of soluble interferon-alpha and its activity in vitro and in vivo. J. Microbiol. Biotechnol,. v.21, p.176-182, 2011.
9. JAIN, R.A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials, v.21, p.2475-2490, 2000.
10. JORGENSEN, L.; MOELLER, E.H.; VAN DE WEERT, M.; NIELSEN, H.M.; FROKJAER, S. Preparing and evaluating delivery systems for proteins. Eur. J. Pharm. Sci., v.29, p.174-182, 2006.
11. LEMMOUCHI, Y.; SCHACHT, E.; LOOTENS, C. In vitro release of trypanocidal drugs from biodegradable implants based on poly(ecaprolactone) and poly(D, L-lactide). J. Control. Release, v.55, p.79-85, 1998.
12. LI, Z.; LI, L.; LIU, Y.; ZHANG, H.; LI, X.; LUO, F.; MEI, X. Development of interferon alpha-2b microspheres with constant release. Int. J. Pharm., v.410, p.48-53, 2011.
13. MERKLI, A.; TABATABAY, C.; GURNY, R.; HELLER, J. Biodegradable polymers for the controlled release of ocular drugs. Prog. Polym. Sci, v.23, p.563-580, 1998.
14. MOHL, S.; WINTER, G. Continuous release of rh-interferon α-2a from triglyceride matrices. J. Control. Release, v.97, p.67-78, 2004.
15. NAM, Y.S.; SONG, S.H.; CHOI, J.Y.; PARK, T.G. Lysozyme microencapsulation within biodegradable PLGA microspheres: urea effect on protein release and stability. Biotechnol. Bioeng., v.70, p.270-277, 2000.
16. PAROLIN, M.B.; RÉA, R.; VARGAS, R.M.; ALMEIDA, A.C.; BALDANZI, G.R.; LOPES, R.W. Prevalence of hepatitis C infection in patients with type 2 Diabetes mellitus. Arq. Gastroenterol., v.43, p.77-80, 2006.
17. RUIZ, L.; REYES, N.; AROCHE, K.; BÁEZ, R.; ALDANA, R.; HARDY, E. Some factors affecting the stability of interferon alpha 2b in solution. Biologicals, v.34, p.15-19, 2006.
18. SÁNCHEZ, A.; TOBÍO, M.; GONZÁLEZ, L.; FABRA, A.; ALONSO, M.J. Biodegradable micro-and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur. J. Pharm. Sci., v.18, p.221-229, 2003.
19. SEGERS, V.F.M.; LEE, R.T. Local delivery of proteins and the use of self-assembling peptides. Drug Discov. Today, v.12, p.561-568, 2007.
20. SICILIANO, R.F.; BOULOS, M. A revision of hepatitis C treatment. Arq. Gastroenterol., v.41, p.1-2, 2004.
21. SINHA, V.R.; BANSAL, K.; KAUSHIK, R.; KUMRIA, R.; TREHAN, V. Poly-e-caprolactone microspheres and nanospheres: an overview. Int. J. Pharm., v.278, p.1-23, 2004.
22. SUN, H.; MEI, L.; SONG, C.; CUI, X.; WANG, P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials, v.27, p.1735-1740, 2006.
23. TEIXEIRA, M.; ALONSO, M.J.; PINTO, M.M.M.; BARBOSA, C.M. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur. J. Pharm. Biopharm., v.59, p.491-500, 2005.
24. THOMAS, C.; GUPTA, V.; AHSAN, F. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int. J. Pharm., v.379, p.41-50, 2009.
25. VERGER, M.L.; FLUCKIGER, L.; KIM, Y.; HOFFMAN, M.; MAINCENT, P. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur. J. Pharm. Biopharm., v.46, p.137-143, 1998.
26. WEIGAND, K.; WOLFGANG, S.; ENCKE, J. Treatment of hepatitis C virus infection. World J. Gastroenterol., v.13, p.1897-1905, 2007.
27. YANG, F.; SONG, F.L.; PAN, Y.F.; WANG, Z.Y.; YANG, Y.Q.; ZHAO, Y.M.; LIANG, S.Z.; ZHANG, Y.M. Preparation and characteristics of interferon-alpha poly (lactic-co-glycolic acid) microspheres. J. Microencapsul., v.27, p.133-141, 2010.